Form 4: Cambrian BioPharma Granted 19,000 Stock Options in Sensei Biotherapeutics

Cambrian BioPharma Inc., a 10% owner and director of Sensei Biotherapeutics, Inc., was granted 19,000 stock options with an exercise price of $0.3202, vesting over one year.

Summary

• Cambrian BioPharma Inc., identified as a Director and 10% Owner of Sensei Biotherapeutics, Inc. (SNSE), reported the acquisition of derivative securities.
• On May 21, 2025, Cambrian BioPharma Inc. was granted 19,000 stock options (Right to Buy) for Sensei Biotherapeutics common stock.
• The exercise price for these options is $0.3202 per share.
• The options vest in 12 equal monthly installments over a one-year period, becoming fully vested on May 21, 2026, or on the date of the Company's next annual stockholder meeting, whichever comes first.
• Vesting is contingent upon the Reporting Person's continuous service with the Issuer.
• The stock options have an expiration date of May 20, 2035.
• Following this transaction, Cambrian BioPharma Inc. beneficially owns 19,000 derivative securities directly.

Sentiment

Score: 7

Explanation: The grant of stock options to a significant owner and director is generally positive as it aligns their interests with long-term shareholder value, indicating continued commitment to the company. However, it's not an immediate financial gain and is subject to vesting conditions and market performance.

Positives

• The grant of stock options to a 10% owner and director aligns their interests with the long-term performance and shareholder value of Sensei Biotherapeutics, Inc.
• The options have a long expiration date (May 20, 2035), providing a significant window for potential value realization.

Negatives

• The options are not immediately exercisable and are subject to a one-year vesting schedule.
• The value of the options is contingent on the future stock price of Sensei Biotherapeutics exceeding the exercise price of $0.3202.

Risks

• The vesting of the stock options is subject to the Reporting Person's continuous service with Sensei Biotherapeutics, Inc.; if service ceases, unvested options may be forfeited.

Future Outlook

The future outlook for Cambrian BioPharma Inc.'s stake in Sensei Biotherapeutics, Inc. includes the vesting of 19,000 stock options over the next year, contingent on continuous service, which could lead to increased beneficial ownership of common stock.

Industry Context

This filing represents a standard equity grant to a director and significant owner, a common practice in the biotechnology and pharmaceutical industries to incentivize long-term commitment and align interests with company performance.

Stakeholder Impact

• Shareholders: The grant of options to a significant owner and director can be seen as a positive step towards aligning management and ownership interests with long-term shareholder value.
• Employees: While this specific grant does not directly impact the broader employee base, it reflects a common compensation strategy that may also be applied to other key personnel.

Next Steps

• The stock options will vest in 12 equal monthly installments over the next year, with full vesting expected by May 21, 2026, or the date of the next annual stockholder meeting, subject to continuous service.

Key Dates

Recommendation

Keywords

Sensei Biotherapeutics, SNSE, Cambrian BioPharma, Stock Option, Form 4, Insider Transaction, Beneficial Ownership, Equity Grant, Derivative Securities